VIR BIOTECHNOLOGY INC

GSK and Vir Biotechnology Announce United States Government Agreement to Purchase Additional Supply of Sotrovimab, Authorized for the Early Treatment of COVID-19

11 Jan 2022 07:12:38 By Nasdaq GlobeNewswire

Vir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 16:02:00 By Nasdaq GlobeNewswire

Vir Biotechnology Announces New Research Describing the Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor Engagement

31 Dec 2021 08:46:58 By Nasdaq GlobeNewswire

Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19

17 Dec 2021 08:16:38 By Nasdaq GlobeNewswire

Preclinical Data Highlight the Significant Antigenic Shift of the Omicron SARS-CoV-2 Variant and its Effect on the Neutralizing Activity of Monoclonal Antibodies, Convalescent Antibodies and Vaccine-Elicited Antibodies

14 Dec 2021 16:39:59 By Nasdaq GlobeNewswire

Vir Biotechnology Announces Initiation of Phase 2 Clinical Trial Evaluating VIR-2218, Selgantolimod and Nivolumab for the Treatment of Chronic Hepatitis B Virus Infection

09 Dec 2021 08:30:00 By Nasdaq GlobeNewswire

Vir Biotechnology to Host a Call on Sotrovimab’s Retained Activity Against the Omicron SARS-CoV-2 Variant

07 Dec 2021 03:55:07 By Nasdaq GlobeNewswire

Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant

07 Dec 2021 03:48:52 By Nasdaq GlobeNewswire

Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant

02 Dec 2021 02:07:11 By Nasdaq GlobeNewswire

GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment

17 Nov 2021 06:42:43 By Nasdaq GlobeNewswire

Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection at AASLD The Liver Meeting®

12 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19

12 Nov 2021 07:10:00 By Nasdaq GlobeNewswire

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results

04 Nov 2021 16:05:01 By Nasdaq GlobeNewswire

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2021 Financial Results on November 4, 2021

21 Oct 2021 16:05:01 By Nasdaq GlobeNewswire

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2021

15 Oct 2021 08:30:00 By Nasdaq GlobeNewswire

Vir Biotechnology to Participate in the H. C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference

06 Oct 2021 16:05:00 By Nasdaq GlobeNewswire

Vir Biotechnology to Participate in the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference

30 Sep 2021 16:05:00 By Nasdaq GlobeNewswire

Vir Biotechnology to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

08 Sep 2021 16:05:00 By Nasdaq GlobeNewswire

Vir Biotechnology to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

07 Sep 2021 16:05:00 By Nasdaq GlobeNewswire

Vir Biotechnology Announces First Marketing Authorization for its First Commercial Product, Sotrovimab, Granted in Australia

23 Aug 2021 08:30:00 By Nasdaq GlobeNewswire